Rigel Pharmaceuticals Future Growth

Future criteria checks 5/6

Rigel Pharmaceuticals is forecast to grow earnings and revenue by 55.8% and 17.6% per annum respectively. EPS is expected to grow by 55.8% per annum. Return on equity is forecast to be 125.5% in 3 years.

Key information

55.8%

Earnings growth rate

55.8%

EPS growth rate

Biotechs earnings growth	24.4%
Revenue growth rate	17.6%
Future return on equity	125.5%
Analyst coverage	Good
Last updated	08 May 2024

Recent future growth updates

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Mar 08

Recent updates

Little Excitement Around Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Revenues As Shares Take 29% Pounding

May 01

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Mar 08

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Surges 36% Yet Its Low P/S Is No Reason For Excitement

Mar 04

Rigel Pharmaceuticals: Upgrading To A 'Top Idea' Ahead Of Promising Q4/2023 Earnings Report

Feb 23

Lacklustre Performance Is Driving Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Low P/S

Jan 15

What Does The Future Hold For Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)? These Analysts Have Been Cutting Their Estimates

Mar 06

Rigel PharmaceuticalsA Biopharma With A Free Shot On Goal In COVID-19, With A Pipeline As A Safety Net

Feb 01

An Intrinsic Calculation For Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Suggests It's 26% Undervalued

Jan 14

Rigel Pharmaceuticals: New Omicron Variant Keeps Tavalisse Treatment Prospects Alive

Nov 30

Is Rigel Pharmaceuticals (NASDAQ:RIGL) Using Debt In A Risky Way?

Nov 02

Rigel Pharma: Positive Data Supports Use Of Tavalisse In COVID-19 As Variants Subterfuge Vaccines

Sep 06

It's Unlikely That Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) CEO Will See A Huge Pay Rise This Year

May 12

Rigel Pharmaceuticals, Inc. 2021 Q1 - Results - Earnings Call Presentation

May 05

Earnings and Revenue Growth Forecasts

NasdaqGS:RIGL - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	227	49	55	N/A	6
12/31/2025	192	20	30	N/A	6
12/31/2024	150	-10	N/A	N/A	6
3/31/2024	119	-20	-7	-7	N/A
12/31/2023	116	-25	-21	-6	N/A
9/30/2023	129	-24	-36	-21	N/A
6/30/2023	121	-38	-49	-33	N/A
3/31/2023	125	-45	-67	-52	N/A
12/31/2022	116	-59	-74	-74	N/A
9/30/2022	86	-83	-71	-71	N/A
6/30/2022	87	-85	-68	-68	N/A
3/31/2022	77	-85	-1	0	N/A
12/31/2021	139	-18	5	6	N/A
9/30/2021	138	-15	8	9	N/A
6/30/2021	136	-8	-1	0	N/A
3/31/2021	131	-11	-70	-69	N/A
12/31/2020	109	-30	-53	-52	N/A
9/30/2020	106	-28	-48	-46	N/A
6/30/2020	108	-25	-43	-41	N/A
3/31/2020	102	-28	-46	-44	N/A
12/31/2019	59	-67	-43	-42	N/A
9/30/2019	82	-46	-21	-20	N/A
6/30/2019	66	-59	-26	-26	N/A
3/31/2019	57	-64	-37	-36	N/A
12/31/2018	45	-70	-60	-59	N/A
9/30/2018	7	-100	-91	-90	N/A
6/30/2018	3	-93	-89	-88	N/A
3/31/2018	1	-87	-81	-80	N/A
12/31/2017	4	-78	N/A	-78	N/A
9/30/2017	7	-68	N/A	-70	N/A
6/30/2017	10	-73	N/A	-75	N/A
3/31/2017	19	-67	N/A	-74	N/A
12/31/2016	20	-69	N/A	-76	N/A
9/30/2016	26	-66	N/A	-77	N/A
6/30/2016	35	-50	N/A	-64	N/A
3/31/2016	32	-51	N/A	-64	N/A
12/31/2015	29	-51	N/A	-23	N/A
9/30/2015	29	-61	N/A	-25	N/A
6/30/2015	16	-75	N/A	-34	N/A
3/31/2015	10	-87	N/A	-35	N/A
12/31/2014	8	-91	N/A	-70	N/A
9/30/2014	6	-85	N/A	-74	N/A
6/30/2014	6	-88	N/A	-76	N/A
3/31/2014	7	-86	N/A	-77	N/A
12/31/2013	7	-89	N/A	-86	N/A
9/30/2013	1	-98	N/A	-89	N/A
6/30/2013	1	-99	N/A	-88	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: RIGL is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.4%).

Earnings vs Market: RIGL is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: RIGL is expected to become profitable in the next 3 years.

Revenue vs Market: RIGL's revenue (17.6% per year) is forecast to grow faster than the US market (8.3% per year).

High Growth Revenue: RIGL's revenue (17.6% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: RIGL's Return on Equity is forecast to be very high in 3 years time (125.5%).

Rigel Pharmaceuticals Future Growth

Future criteria checks 5/6

Key information

Recent future growth updates

Price target increased by 14% to US$5.08

Consensus EPS estimates fall by 13%

Consensus estimates of losses per share improve by 12%

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Forecast breakeven date moved forward to 2025

Price target increased by 10% to US$4.46

Recent updates

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Little Excitement Around Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Revenues As Shares Take 29% Pounding

Rigel Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 07, 2024

Price target increased by 14% to US$5.08

Rigel Pharmaceuticals, Inc., Annual General Meeting, May 22, 2024

Consensus EPS estimates fall by 13%

Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer as Chief Medical Officer

Consensus estimates of losses per share improve by 12%

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Forecast breakeven date moved forward to 2025

Price target increased by 10% to US$4.46

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Surges 36% Yet Its Low P/S Is No Reason For Excitement

Rigel Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 05, 2024

Rigel Pharmaceuticals: Upgrading To A 'Top Idea' Ahead Of Promising Q4/2023 Earnings Report

President recently sold US$60k worth of stock

Lacklustre Performance Is Driving Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Low P/S

No longer forecast to breakeven

New minor risk - Share price stability

Forecast to breakeven in 2025

Rigel Pharmaceuticals, Inc. Receives A Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC

Consensus EPS estimates upgraded to US$0.19 loss

Forecast to breakeven in 2025

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Rigel Pharmaceuticals, Inc. Announces Poster Presentations At the 65Th American Society of Hematology Annual Meeting and Exposition

Rigel Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Rigel Pharmaceuticals, Inc. Announces Presentation of Data from the Focus Phase 3 Clinical Trial of Fostamatinib in Hospitalized COVID-19 Patients and Provides Update on ACTIV-4 Host Tissue Trial

Consensus EPS estimates upgraded to US$0.25 loss

New minor risk - Profitability

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Rigel Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 01, 2023

Rigel Pharmaceuticals, Inc. Announces Presentation of Data from Analysis of REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML

Rigel Pharmaceuticals, Inc. Announces Second -2-2-Appointment of Olutasidenib as Therapeutics

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Forecast to breakeven in 2025

Price target increased by 7.6% to US$3.85

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Rigel Pharmaceuticals, Inc. Announces Resignation of Wolfgang Dummer as Executive Vice President and Chief Medical Officer, Effective March 31, 2023

Rigel Pharmaceuticals, Inc. Announces Publication of REZLIDHIA (Olutasidenib) Phase 2 Clinical Results in Blood Advances

National Comprehensive Cancer Network Adds Newly Approved Rigel Pharmaceuticals, Inc.'s REZLIDHIA™ (Olutasidenib) to Clinical Practice Guidelines in Oncology for Acute Myeloid Leukemia

Price target increased to US$4.11

Rigel Pharmaceuticals, Inc. Provides Revenue Guidance for the Fourth Quarter of 2022

Rigel Pharmaceuticals, Inc. Announces Availability of REZLIDHIA™ (olutasidenib) in the U.S. for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation

Rigel Pharmaceuticals, Inc. Doses First Patient in Phase 1b Study of R289 for the Treatment of Lower-Risk Myelodysplastic Syndromes

Rigel Pharmaceuticals, Inc. Announces U.S. FDA Approval of REZLIDHIA™ (olutasidenib) for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation

Rigel Pharmaceuticals Received a Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Rigel Pharmaceuticals, Inc. Announces Publication of Early Clinical Data of Olutasidenib in the Lancet Haematology

Third quarter 2022 earnings: EPS exceeds analyst expectations

Rigel Pharmaceuticals, Inc. Announces Top-Line Results from Focus Phase 3 Clinical Trial of Fostamatinib in High Risk Hospitalized Covid-19 Patients

Rigel Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Is Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Trading At A 25% Discount?

Now 22% undervalued after recent price drop

Rigel Pharmaceuticals, Inc. Provides Update on Plans for sNDA for wAIHA Program Following FDA Feedback

Rigel cutting 16% of workforce after declining to file sNDA for fostamatinib

Now 21% undervalued

Price target decreased to US$2.08

Rigel Pharma adds ~7% to reach over two month high

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Rigel rises 17% on strong Q2 result

Rigel Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 02, 2022

President recently bought US$688k worth of stock

Rigel Pharmaceuticals, Inc. Announces Top-Line Results from Forward Phase 3 Clinical Trial of Fostamatinib in Patients with Warm Autoimmune Hemolytic Anemia

Rigel Pharmaceuticals: A Status Check

Consensus forecasts updated

No longer forecast to breakeven

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$7.29

Is Rigel Pharmaceuticals (NASDAQ:RIGL) A Risky Investment?

Rigel Pharmaceuticals, Inc., Annual General Meeting, May 19, 2022

Price target decreased to US$7.29